90724-57-5

Basic information

• Product Name: Pyrrole-2-carboxylic acid, 3-methyl- (6CI,7CI)
• Synonyms: Pyrrole-2-carboxylic acid, 3-methyl- (6CI,7CI);Pyrrole-2-carboxylic acid, 3-methyl-;3-Methyl-1H-pyrrole-2-carboxylicacid
• CAS NO: 90724-57-5
• Molecular Formula: C₆H₇NO₂
• Molecular Weight: 125.12
• Product Categories: PYRROLE
• Mol File: 90724-57-5.mol

Chemical Properties

• Boiling Point: 322.4 °C at 760 mmHg
• Flash Point: 148.8 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Pyrrole-2-carboxylic acid, 3-methyl- (6CI,7CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrole-2-carboxylic acid, 3-methyl- (6CI,7CI)(90724-57-5)
• EPA Substance Registry System: Pyrrole-2-carboxylic acid, 3-methyl- (6CI,7CI)(90724-57-5)

Safety Data

• Hazardous Substances Data: 90724-57-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Pyrrole-2-carboxylic acid, 3-methyl(6CI,7CI) serves as a valuable intermediate in organic synthesis, facilitating the construction of complex organic molecules. Its presence in various chemical reactions contributes to the formation of a wide array of compounds with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Pyrrole-2-carboxylic acid, 3-methyl(6CI,7CI) is utilized as a key component in the development of new drugs. Its unique structure allows it to be incorporated into medicinal compounds, potentially leading to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
Pyrrole-2-carboxylic acid, 3-methyl(6CI,7CI) also finds application in the agrochemical sector, where it is employed in the synthesis of pesticides and other crop protection agents. Its integration into these products can enhance their effectiveness in protecting crops from pests and diseases.
Used in Medicinal Chemistry Research:
Pyrrole-2-carboxylic acid, 3-methyl(6CI,7CI) holds promise in medicinal chemistry research, where it is studied for its potential to interact with biological targets, such as enzymes and receptors. This research can lead to a better understanding of its pharmacological properties and its potential use in the treatment of various diseases.
Used in Drug Discovery:
Pyrrole-2-carboxylic acid, 3-methyl(6CI,7CI) is a candidate in drug discovery processes, where its unique structural features are explored for the development of new pharmaceutical entities. Its versatility in chemical modifications makes it an attractive scaffold for designing drugs with specific therapeutic goals.

InChI:InChI=1/C6H7NO2/c1-4-2-3-7-5(4)6(8)9/h2-3,7H,1H3,(H,8,9)

Upstream product

• 3284-53-5 3-methyl-1-p-toluenesulfonyl-2,5-dihydro-1H-pyrrole-2-carboxylic acid ethyl ester 
• 3284-52-4 ethyl 3-hydroxy-3-methyl-1-p-toluenesulfonylpyrrolidine-2-carboxylate 
• 40611-69-6 methyl 3-methyl-1H-pyrrole-2-carboxylate 
• 90610-57-4 3-methyl-pyrrole-2,4-dicarboxylic acid-2-ethyl ester 
• 3284-47-7 ethyl 3-methyl-1H-pyrrole-2-carboxylate 

Downstream Products

• 1403941-98-9 1-amino-3-methyl-N-(o-tolyl)-1H-pyrrole-2-carboxamide 
• 1194094-45-5 3-methyl-1H-pyrrole-2-carboxylic acid [(S)-1-[(6-amino-pyridin-3-ylmethyl)-carbamoyl]-2-(3,4-difluoro-phenyl)-ethyl]-amide trifluoroacetate 

Relevant articles and documents

Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2 H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors

The bromodomain and extra-terminal (BET) family proteins have recently emerged as promising drug targets for cancer therapy. In this study, identification of an 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one fragment (47) as a new binder to the BET bromodomains

Synthesis process method of 3-substituted-1H-pyrrole

The invention provides a synthetic process method of a 3-substituted-1H-pyrrole compound. The process method comprises the following steps: by taking diethylamine hydrochloride and glycine ethyl esterhydrochloride as initial raw materials, respectively carrying out Mannich reaction and sulfamide reaction, and carrying out cyclization reaction, dehydration thinning reaction, aromatization reactionand hydrolysis decarboxylation reaction to obtain a 3-substituted-1H-pyrrole compound. According to the synthesis process method of the 3-substituted-1H-pyrrole compound, the whole synthesis route isgood in step repeatability, mild in operation condition and high in safety, and large-scale production and industrial popularization are facilitated; post-treatment energy consumption is low, a largeamount of toxic wastewater is not generated, no pollution is caused to the environment, the production safety level and the production cost are reduced, application of green and environment-friendlyindustrial production is facilitated, and wide application prospects are achieved.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

Pyrrolotriazinone derivatives as PI3K inhibitors

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)